Internal irradiation therapy for metastatic bone cancer

Bone cancer can be divided into two categories: primary and secondary. Secondary bone cancer mostly originates from the lungs. In addition, malignant tumors in the thyroid, breast, stomach, liver, kidney, prostate and other parts of the body are also prone to bone metastasis. About 1/3 of patients are diagnosed with primary cancer and bone metastasis during examinations due to bone pain. At this time, the patients are already in the late stage of cancer and most die within half a year.

Internal irradiation therapy has a good effect on metastatic bone cancer. The main drug used is 153-Sm-EDTMP (153-Sm-ethylenediaminetetramethylphosphonic acid). The principle of its treatment is that 153-Sm-EDTMP has a high affinity with bone tumor lesions. After taking the drug, its concentration in bone tumor lesions is ten, a hundred, or even a thousand times higher than the normal distribution. It emits high-energy rays, which can effectively kill bone tumor cells, thereby playing a therapeutic role. Since this drug can be highly concentrated in all bone metastatic tumor lesions through biological metabolic pathways after entering the human body, it is also known as "guided therapy" and "biological missiles", just like missiles can destroy targets in a targeted manner. Clinical applications have shown that the use of this drug can not only effectively inhibit and eliminate bone metastatic lesions, but also most patients can gradually eliminate severe bone pain within 6 to 12 hours after taking the drug. It can also prevent the occurrence of new metastatic lesions, significantly improving the quality of life of patients.